Abstract
Oncolytic viruses can selectively replicate in and lead to tumor cell lysis with minimal infection/replication potential in adjoining non-neoplastic tissue. Because of paramount safety concerns, first-generation oncolytic viruses were designed to be significantly attenuated in their lytic potential. Results from recent clinical trials have revealed the safety of this approach, but have underscored the urgency for design and testing of more tumor-selective and -potent viruses to realize the full therapeutic potential of this revolutionary treatment modality. With the discovery of various molecular/genetic changes associated with neoplasia, tumor-specific transcriptional targeting of viral virulence is being tapped to generate tumor- and tissue-specific variants. This review will focus on the various strategies exploited to generate viruses whose virulence is governed by tumorspecific transcriptional events.
Keywords: Oncolytic viruses, adenovirus, HSV-1, cancer, transcriptional regulation, promoter
Current Cancer Drug Targets
Title: Oncolytic Viruses Driven by Tumor-Specific Promoters
Volume: 7 Issue: 2
Author(s): Jayson Hardcastle, Kazuhiko Kurozumi, E. Antonio Chiocca and Balveen Kaur
Affiliation:
Keywords: Oncolytic viruses, adenovirus, HSV-1, cancer, transcriptional regulation, promoter
Abstract: Oncolytic viruses can selectively replicate in and lead to tumor cell lysis with minimal infection/replication potential in adjoining non-neoplastic tissue. Because of paramount safety concerns, first-generation oncolytic viruses were designed to be significantly attenuated in their lytic potential. Results from recent clinical trials have revealed the safety of this approach, but have underscored the urgency for design and testing of more tumor-selective and -potent viruses to realize the full therapeutic potential of this revolutionary treatment modality. With the discovery of various molecular/genetic changes associated with neoplasia, tumor-specific transcriptional targeting of viral virulence is being tapped to generate tumor- and tissue-specific variants. This review will focus on the various strategies exploited to generate viruses whose virulence is governed by tumorspecific transcriptional events.
Export Options
About this article
Cite this article as:
Hardcastle Jayson, Kurozumi Kazuhiko, Antonio Chiocca E. and Kaur Balveen, Oncolytic Viruses Driven by Tumor-Specific Promoters, Current Cancer Drug Targets 2007; 7 (2) . https://dx.doi.org/10.2174/156800907780058880
DOI https://dx.doi.org/10.2174/156800907780058880 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Smart Stimuli Sensitive Nanogels in Cancer Drug Delivery and Imaging: A Review
Current Pharmaceutical Design Gamma Secretase Inhibitor: Therapeutic Target via NOTCH Signaling in T Cell Acute Lymphoblastic Leukemia
Current Drug Targets Brachytherapy: State of the Art and Possible Improvements
Anti-Cancer Agents in Medicinal Chemistry Protein Kinases as Tumor Biomarkers and Therapeutic Targets
Current Pharmaceutical Design Mesenchymal Stem Cells for Treatment of CNS Injury
Current Neuropharmacology Some Wild-Growing Plant Species from Serbia and Montenegro as the Potential Sources of Drugs
Current Pharmaceutical Design Anticancer Drug Design Using Scaffolds of β-Lactams, Sulfonamides, Quinoline, Quinoxaline and Natural Products. Drugs Advances in Clinical Trials
Current Medicinal Chemistry Current Drug Targets for Modulating Alzheimer's Amyloid Precursor Protein: Role of Specific Micro-RNA Species
Current Medicinal Chemistry The Effects of Insulin and Insulin-Like Growth Factors on Tumor Vascularization: New Insights of Insulin-Like Growth Factor Family in Cancer
Current Medicinal Chemistry Anti-Cancer Phytometabolites Targeting Cancer Stem Cells
Current Genomics p53: Fighting Cancer
Current Cancer Drug Targets Drug Targeting Strategies in Cancer Treatment: An Overview
Mini-Reviews in Medicinal Chemistry Cyclooxygenase-2: Potential Role in Regulation of Drug Efflux and Multidrug Resistance Phenotype
Current Pharmaceutical Design The Role of Fibroblast Growth Factors in Tumor Growth
Current Cancer Drug Targets Flavonoids as Prospective Aromatase Inhibitors in Breast Cancer Prevention/ Therapy
Current Molecular Pharmacology The Ubiquitin-Proteasome System (UPS) and the Mechanism of Action of Bortezomib
Current Pharmaceutical Design Targeting Pattern Recognition Receptors (PRRs) in Nano- Adjuvants: Current Perspectives
Current Bionanotechnology (Discontinued) Novel Indications for Benzodiazepine Antagonist Flumazenil in GABA Mediated Pathological Conditions of the Central Nervous System
Current Pharmaceutical Design Proteomic and Metallomic Strategies for Understanding the Mode of Action of Anticancer Metallodrugs
Anti-Cancer Agents in Medicinal Chemistry Preclinical Studies of Alkylureas as Anti-HIV-1 Contraceptive
Current Pharmaceutical Design